Clinical efficacy of bortezomib and lenalidomide in blastic plasmacytoid dendritic cell neoplasm
Letter to the Editor
First Online:
- 37 Downloads
Notes
Authors’ contributions
Each author was involved in the writing of the manuscript. All authors approved the final manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
Informed consent
Informed consent was obtained from the participating patient of the case description.
References
- 1.Bueno C, Almeida J, Lucio P, Marco J, Garcia R, de Pablos JM, Parreira A, Ramos F, Ruiz-Cabello F, Suarez-Vilela D, San Miguel JF, Orfao A (2004) Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica 89:58–69Google Scholar
- 2.Martin-Martin L, Lopez A, Vidriales B et al (2015) Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget 6:19204–19216CrossRefGoogle Scholar
- 3.Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M, Meijer CJLM, Courville P, Joly P, Grange F, de Muret A, Machet L, Dompmartin A, Bosq J, Durlach A, Bernard P, Dalac S, Dechelotte P, D’Incan M, Wechsler J, Teitell MA (2005) Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms). Am J Clin Pathol 123:662–675CrossRefGoogle Scholar
- 4.Sapienza MR, Fuligni F, Agostinelli C et al (2014) Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia 28:1606–1616CrossRefGoogle Scholar
- 5.Remco Dijkman RVDK (2007) Gene-expression profiling and array-based CGH classify CD4+CD56+hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 109:1720–1727CrossRefGoogle Scholar
- 6.Philippe L, Ceroi A, Bôle-Richard E, Jenvrin A, Biichle S, Perrin S, Limat S, Bonnefoy F, Deconinck E, Saas P, Garnache-Ottou F, Angelot-Delettre F (2017) Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm. Haematologica 102:1861–1868CrossRefGoogle Scholar
Copyright information
© Springer-Verlag GmbH Germany, part of Springer Nature 2019